A New Noncanonical Anionic Peptide That Translocates a Cellular Blood–Brain Barrier Model
The capacity to transport therapeutic molecules across the blood–brain barrier (BBB) represents a breakthrough in the development of tools for the treatment of many central nervous system (CNS)-associated diseases. The BBB, while being protective against infectious agents, hinders the brain uptake o...
Main Authors: | Sara Neves-Coelho, Rute P. Eleutério, Francisco J. Enguita, Vera Neves, Miguel A. R. B. Castanho |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2017-10-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/22/10/1753 |
Similar Items
-
Applications and Challenges for Use of Cell-Penetrating Peptides as Delivery Vectors for Peptide and Protein Cargos
by: Mie Kristensen, et al.
Published: (2016-01-01) -
Conjugation of Therapeutic PSD-95 Inhibitors to the Cell-Penetrating Peptide Tat Affects Blood–Brain Barrier Adherence, Uptake, and Permeation
by: Mie Kristensen, et al.
Published: (2020-07-01) -
SPA: a peptide antagonist that acts as a cell-penetrating peptide for drug delivery
by: Jingjing Song, et al.
Published: (2020-01-01) -
Peptide-based vectors: recent developments
by: Cerrato Carmine Pasquale, et al.
Published: (2014-12-01) -
Developments and Applications of Cyclic Cell Penetrating Peptides
by: Qian, Ziqing
Published: (2014)